Regulatory Comments
ICLE Comment on FTC/DOJ Listening Session on Anticompetitive Conduct by Pharmaceutical Companies Impeding Generic or Biosimilar Competition
Please find attached my article, “First Impressions from the DOJ/FTC Listening Session on Drug-Price Competition.” In it, I analyze the competing reform proposals discussed during the session, with particular attention to their implications for innovation incentives, patient access, and the balance between patent protections and generic entry. My aim is to contribute a law & economics perspective that emphasizes targeted enforcement over systemic disruption, and to highlight how preserving the U.S. model of pharmaceutical competition can best serve patients and innovation alike.